Skip to content

Kenneth W. Turteltaub

5 papers in the library · 37 citations · publishing 2009-2011

Papers

Sort Most recent Most cited

Abstract LB-403: A Phase 0 microdosing clinical trial to identify chemoresistance

Cancer Research April 15, 2011 Chong-Xian Pan, Sisi Wang, Ralph De Vere White et al.

Abstract BACKGROUND: As alkylating agents, platinum (Pt) analogs kill cancer cells mainly through induction of DNA damage. We hypothesize that low levels of Pt-induced DNA damage are predictive of chemoresistance. Accelerator mass spectrometry (AMS) is an ultrasensitive method for measuring radiocarbon with 10−18∼21 mole sensitivity. By measuring 14C bound to DNA, AMS detects...

A phase 0 microdosing trial to identify chemoresistance in bladder cancer.

Journal of Clinical Oncology March 1, 2011 C. Pan, S. Wang, M. He et al.

264 Background: DNA damage is the critical step in cancer cell response to platinum (Pt) chemotherapy. We hypothesize that low levels of Pt-induced DNA damage are predictive of chemoresistance. Accelerator mass spectrometry (AMS) is an ultrasensitive method for measuring radiocarbon. By measuring 14C bound to DNA, AMS can detect carboplatin-induced DNA damage after patients receive one subtoxic...

A microdosing approach for characterizing formation and repair of carboplatin–DNA monoadducts and chemoresistance

International Journal of Cancer December 2, 2010 Paul T. Henderson, Tao Li, Miaoling He et al. 37 citations

Formation and repair of platinum (Pt)-induced DNA adducts is a critical step in Pt drug-mediated cytotoxicity. Measurement of Pt-DNA adduct kinetics in tumors may be useful for better understanding chemoresistance and therapeutic response. However, this concept has yet to be rigorously tested because of technical challenges in measuring the adducts at low concentrations and consistent access to...

Abstract 3522: A Phase 0 microdosing trial to identify chemoresistance: From bench to bedside

Cancer Research April 15, 2010 Sisi Wang, Miaoling He, Tao Li et al.

Abstract BACKGROUND: DNA damage is the critical step in cancer cell response to platinum (Pt) chemotherapy. We hypothesize that low levels of Pt-induced DNA damage are predictive of chemoresistance. Accelerator mass spectrometry (AMS) is an ultrasensitive method for measuring radiocarbon. By measuring 14C bound to DNA, AMS can detect carboplatin-induced DNA damage after patients receive one...

Design of a phase 0 microdosing trial for correlation of platinum-induced DNA damage to chemotherapy outcomes

Journal of Clinical Oncology May 20, 2009 C. Pan, T. Li, M. He et al.

2543 Background: DNA damage is the critical step in cancer cell response to platinum (Pt) chemotherapy. We hypothesize that low levels of Pt-induced DNA damage are predictive of chemoresistance. Accelerator mass spectrometry (AMS), an ultrasensitive method for measuring radiocarbon, can detect [14C]carboplatin bound to the DNA of cancer cells from cell culture, mice bearing tumor xenografts and...